<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05081141</url>
  </required_header>
  <id_info>
    <org_study_id>S_OTTO</org_study_id>
    <nct_id>NCT05081141</nct_id>
  </id_info>
  <brief_title>HHV8 and Solid Organ Transplantation</brief_title>
  <official_title>Screening for HHV8 Infection in Solid Organ Transplantation Donors, Candidates and Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Solid organ transplant candidates will undergo serological screening for HHV8 at time of&#xD;
      listing and transplantation.&#xD;
&#xD;
      In the event of a recipient/donor mismatch R-/D+ or in the presence of a seropositive&#xD;
      recipient (R+), blood levels of HHV8 DNA will be monitored together with specific IGRA for&#xD;
      HHV8.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients on the waiting list for solid organ transplantation will undergo serological&#xD;
      screening for HHV8 (lytic and latent antigens) in the pre-transplant phase, both at time of&#xD;
      listing and then at the time of transplantation; if seropositivity is found, further&#xD;
      investigations will be performed, i.e. blood levels of HHV8 DNA and specific Elispot for&#xD;
      HHV8.&#xD;
&#xD;
      As for donors, serological testing for HHV8 (lytic and latent antigens) will be performed.&#xD;
&#xD;
      AFTER SOLID ORGAN TRANSPLANTATION&#xD;
&#xD;
        -  Patients found HHV8 seropositive in the pretransplant phase (R +), being at risk of HHV8&#xD;
           reactivation, will be monitored monthly in terms of viremia (HHV8 DNA) and specific IGRA&#xD;
           for HHV8 for the first 6 months after transplantation and subsequently every 3 months up&#xD;
           to 12 months post transplant.&#xD;
&#xD;
        -  In case of patients who were found HHV8 seronegative at time of transplantation, donor&#xD;
           serology will be evaluated. In case of R-/D+ mismatch, SOT recipients will receive the&#xD;
           same monitoring of R + patients (blood levels of HHV8 DNA and specific IGRA for HHV8&#xD;
           monthly for the first 6 months and then every 3 months up to 12 months after&#xD;
           transplantation).&#xD;
&#xD;
        -  With reference to lung transplant patients, in cases of R + or R- / D +, HHV8 DNA will&#xD;
           also be searched on the BAL obtained during surveillance bronchoscopies (usually at 3, 6&#xD;
           and 12 months after transplantation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of HHV8 seropositivity among SOT donors and recipients</measure>
    <time_frame>2021-2024</time_frame>
    <description>Incidence of HHV8 seropositivity among solid organ transplantations donors, candidates and recipients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HHV8 mismatch between SOT donors and recipients</measure>
    <time_frame>2021-2024</time_frame>
    <description>Incidence of HHV8 mismatch between solid organ transplantations donors and recipients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of HHV8 related disease after solid organ transplantation</measure>
    <time_frame>2021-2025</time_frame>
    <description>Incidence of HHV8 related disease after solid organ transplantation</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>HHV8</condition>
  <condition>HHV8 Infection</condition>
  <condition>HHV8-Related Malignant Neoplasm</condition>
  <condition>Kaposi Sarcoma</condition>
  <condition>Lung Transplant; Complications</condition>
  <condition>Liver Transplant; Complications</condition>
  <condition>Kidney Transplant; Complications</condition>
  <condition>Castleman Disease</condition>
  <arm_group>
    <arm_group_label>SOT Donors</arm_group_label>
    <description>Solid organ transplantation donors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LuTx candidates and recipients</arm_group_label>
    <description>Lung transplant candidates and recipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTx candidates and recipients</arm_group_label>
    <description>Liver transplant candidates and recipients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KTx candidates and recipients</arm_group_label>
    <description>Kidney transplant candidates and recipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Diagnostic test for HHV8 exposure</intervention_name>
    <description>Venipuncture for blood sampling</description>
    <arm_group_label>KTx candidates and recipients</arm_group_label>
    <arm_group_label>LTx candidates and recipients</arm_group_label>
    <arm_group_label>LuTx candidates and recipients</arm_group_label>
    <arm_group_label>SOT Donors</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We will include all the donors being used for transplantation purposes at our centre and&#xD;
        the respective recipients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        SOT DONORS:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  all donors used for transplantation purposes (kidney, liver, lung), including living&#xD;
             donors in case of kidney transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
&#xD;
        SOT CANDIDATES RECIPIENTS:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients listed for solid organ transplantation (lung, liver and kidney)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valeria Rossetti, MD</last_name>
    <phone>0039 2 55033782</phone>
    <email>valeria.rossetti@policlinico.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Letizia Corinna Morlacchi, MD</last_name>
    <phone>0039 2 55033782</phone>
    <email>letizia.morlacchi@policlinico.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeria Rossetti, MD</last_name>
      <phone>00393395605478</phone>
      <email>valeria.rossetti@policlinico.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Letizia Corinna Morlacchi, MD</last_name>
      <phone>00393338158766</phone>
      <email>letizia.morlacchi@policlinico.mi.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Polizzotto MN, Uldrick TS, Wyvill KM, Aleman K, Marshall V, Wang V, Whitby D, Pittaluga S, Jaffe ES, Millo C, Tosato G, Little RF, Steinberg SM, Sereti I, Yarchoan R. Clinical Features and Outcomes of Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV)-associated Inflammation: Prospective Characterization of KSHV Inflammatory Cytokine Syndrome (KICS). Clin Infect Dis. 2016 Mar 15;62(6):730-738. doi: 10.1093/cid/civ996. Epub 2015 Dec 12. Erratum in: Clin Infect Dis. 2018 Mar 5;66(6):985.</citation>
    <PMID>26658701</PMID>
  </reference>
  <reference>
    <citation>Chiereghin A, Barozzi P, Petrisli E, Piccirilli G, Gabrielli L, Riva G, Potenza L, Cappelli G, De Ruvo N, Libri I, Maggiore U, Morelli MC, Potena L, Todeschini P, Gibertoni D, Labanti M, Sangiorgi G, La Manna G, Pinna AD, Luppi M, Lazzarotto T. Multicenter Prospective Study for Laboratory Diagnosis of HHV8 Infection in Solid Organ Donors and Transplant Recipients and Evaluation of the Clinical Impact After Transplantation. Transplantation. 2017 Aug;101(8):1935-1944. doi: 10.1097/TP.0000000000001740.</citation>
    <PMID>28333859</PMID>
  </reference>
  <reference>
    <citation>Pietrosi G, Vizzini G, Pipitone L, Di Martino G, Minervini MI, Lo Iacono G, Conaldi PG, Grossi P, Lamonaca V, Galatioto L, Gruttadauria S, Gridelli B. Primary and reactivated HHV8 infection and disease after liver transplantation: a prospective study. Am J Transplant. 2011 Dec;11(12):2715-23. doi: 10.1111/j.1600-6143.2011.03769.x. Epub 2011 Oct 3.</citation>
    <PMID>21966899</PMID>
  </reference>
  <reference>
    <citation>Riva G, Luppi M, Barozzi P, Forghieri F, Potenza L. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood. 2012 Nov 15;120(20):4150-9. doi: 10.1182/blood-2012-04-421412. Epub 2012 Sep 11.</citation>
    <PMID>22968461</PMID>
  </reference>
  <reference>
    <citation>Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.</citation>
    <PMID>28783452</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HHV8</keyword>
  <keyword>Solid organ transplant</keyword>
  <keyword>Lung transplant</keyword>
  <keyword>Liver transplant</keyword>
  <keyword>Kidney transplant</keyword>
  <keyword>Kaposi Sarcoma</keyword>
  <keyword>Castleman Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Castleman Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

